What patients pay for ChondroFiller at London Cartilage Clinic

Guide costs for ChondroFiller at London Cartilage Clinic follow a straightforward three-tier structure based on how many boxes of the implant are required: one box costs £3,000, two boxes £5,500, and three boxes £8,000. These are all-inclusive figures — there is no separate charge for the consultation and imaging review, the real-time ultrasound guidance used during the appointment, the ChondroFiller implant itself, the outpatient injection, IV antibiotic cover, or the six-week follow-up.

The number of boxes needed depends on the size and location of the cartilage defect and is confirmed at the initial consultation once imaging has been reviewed. Patients know their total cost before anything is booked; there are no day-of-procedure surprises.

The same three tiers apply regardless of which joint is being treated — knee, hip, shoulder, ankle, and others are all priced on the same scale.

London Cartilage Clinic is currently the only centre in the UK offering ChondroFiller as an ultrasound-guided injection, a service led by Professor Paul Y.F. Lee at 66 Harley Street.

For patients whose defect cannot be addressed via an injection pathway and who require keyhole surgery instead, costs typically start from £9,500. That represents a distinct clinical pathway rather than a variation on the injection service, and suitability for each route is assessed individually at consultation.

Everything the fee covers

Patients comparing private procedure costs often worry about charges that appear only once a booking is confirmed. The fee for a ChondroFiller appointment at London Cartilage Clinic is structured to remove that uncertainty: every element of the episode is covered within the quoted price.

A single all-inclusive fee covers:

• Initial consultation and imaging review — a clinical assessment of your history, symptoms, and existing scans before the appointment is confirmed
• Real-time ultrasound guidance — used throughout the outpatient injection to ensure accurate placement of the scaffold
• The ChondroFiller implant itself — the product is not itemised or billed separately
• IV antibiotic prophylaxis — administered on the day as standard infection precaution
• Six-week post-procedure follow-up — a dedicated review appointment to assess early response

There is no day-of-procedure surcharge and no itemised billing. The figure confirmed at consultation — once the imaging review has established how many boxes are required — is the figure that applies.

Why ChondroFiller costs more than a standard joint injection

ChondroFiller is a CE-marked Class III medical device — the highest regulatory classification for implants under EU and UK rules. That classification reflects what the product is designed to do once it is inside the joint, not a bureaucratic formality.

After injection, the collagen scaffold self-gels at the defect site and recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone. Those cells differentiate within the scaffold through acellular matrix-induced chondrogenesis — producing new cartilaginous tissue from the patient's own biology rather than delivering a lubricant or a temporary anti-inflammatory. Manufacturing a device that performs this role requires a level of clinical testing, quality assurance, and regulatory compliance that standard injectables simply do not face.

Corticosteroid and hyaluronic acid injections are classified as pharmaceutical products, not Class III implants. Neither carries the same development or importation burden, which is why their price points sit in a different range — and why comparing them to ChondroFiller on cost alone is comparing fundamentally different categories of intervention.

ChondroFiller is manufactured by Meidrix Biomedicals GmbH in Germany and imported into the UK under prescription. Supply-chain and regulatory costs are embedded in the product before it reaches the clinic. As a practical matter, the implant itself accounts for the substantial majority of the guide fee — which is also why the three pricing tiers track box count directly. One box, two boxes, or three reflects the quantity of device required, not variation in what the outpatient appointment involves.

CCSD codes and private medical insurance

For patients with private medical insurance, ChondroFiller procedures are billed using two recognised CCSD codes: W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy). Both codes appear on the fee schedules of Bupa, Aviva, and WPA, meaning the procedure has a recognised billing identity within UK private insurance frameworks.

One point worth clarifying: W8500's descriptor — 'arthroscopy' — is the administrative code applied within private billing, not a description of the outpatient injection pathway itself. The ChondroFiller injection is delivered as an ultrasound-guided outpatient appointment, not an arthroscopic or keyhole procedure.

Coverage is neither automatic nor guaranteed. Whether a policy will contribute to the cost depends on the individual policy terms, the insurer's clinical criteria, and the specifics of the patient's case. Some insurers may fund part of the procedure but not the full amount, and reimbursement rates are not publicly listed — patients will need to contact their insurer directly to understand what their policy may contribute.

Written pre-authorisation must be obtained from the insurer before booking the procedure. Requesting authorisation after treatment has taken place is unlikely to result in a successful claim. When contacting the insurer, quoting both CCSD codes — W3111 and W8500 — gives the claims team the reference points needed to check the relevant fee schedule.

The insurance information above was current as of October 2025. Insurer policies and coverage criteria can change, so it is worth confirming the position directly with the relevant insurer at the time of enquiry.

Combination therapy options and their pricing

Beyond the standalone injection, London Cartilage Clinic offers two higher-tier packages for patients whose clinical picture points toward a combined approach.

The first is a dual-injection pathway pairing ChondroFiller with Arthrosamid, priced at £6,000. The two products are not interchangeable and should not be read as variations on a single treatment. ChondroFiller provides the regenerative scaffold component — working through the mechanism described in the previous section — whilst Arthrosamid is a polyacrylamide hydrogel that acts as a structural cushion within the joint space. It is not a regenerative therapy; its role is distinct from cartilage repair, addressing a different aspect of joint function. Combining them means targeting two separate mechanisms simultaneously, not doubling up on the same intervention.

The second option is the Tri-Active Therapy, which adds autologous mesenchymal stem cells to the ChondroFiller and Arthrosamid combination, priced at £11,000.

A longitudinal maintenance programme is also available, incorporating recurring MRI, peptide support, and bi-annual ChondroFiller top-ups — structured for patients who wish to monitor and sustain joint health over the longer term.

None of these combinations are prescribed as a default. Which pathway — if any — is appropriate depends on the individual patient's imaging, symptom profile, and treatment history, and is explored at consultation rather than assumed.

Who is eligible and what to do next

Eligibility is assessed individually, with no blanket exclusions based on age or defect size. Patients who have previously been told they do not qualify for standard cartilage repair procedures — whether because the defect is considered too large, the joint too complex, or age a complicating factor — may still be suitable candidates for the ChondroFiller injection pathway. The initial consultation, which includes an imaging review, is the stage at which suitability is properly determined.

In published cohort data, 70–85% of treated patients achieve significant symptom relief — meaningful reductions in pain and improvements in mobility. As with any intervention, outcomes vary by individual, and those figures come from reported series rather than a guarantee.

ChondroFiller is not available on the NHS. Autologous chondrocyte implantation (ACI) remains the only cell-based cartilage therapy currently funded through NHS pathways for knee defects; ChondroFiller sits outside that provision and is funded privately or, where pre-authorisation is granted, through a private medical insurance policy.

For patients in London, an assessment with Professor Paul Y. F. Lee at London Cartilage Clinic on Harley Street is the starting point. Appointments can be booked at londoncartilage.com.